Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.
Intensive Care Med. 2015;41(1):164-5.
MeSH terms: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; France; Humans; Intensive Care Units; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Patient Admission; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Survival Analysis; Treatment Outcome
DOI: 10.1007/s00134-014-3535-x